Company news
Kiora Pharmaceuticals, Inc. news in 2022
Kiora Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants
November 17, 2022
Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa
November 16, 2022
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
November 8, 2022
Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
October 16, 2022
Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
October 12, 2022
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split
September 25, 2022
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
September 12, 2022
Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
August 11, 2022
Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
July 25, 2022
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
July 21, 2022
Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
July 4, 2022
Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
June 26, 2022
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
April 24, 2022
Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update
April 14, 2022
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
March 17, 2022
Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
February 7, 2022
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
January 31, 2022
Decks in 2022
- IPO Roadshow (July 2022)
IPO roadshow · 34 slides · Jul 14, 2022
- Investor Presentation (January 2022)
Investor deck · 31 slides · January 2022